FDA cautioned to better regulate nanomaterials

A public hearing called by the FDA turned into a forum to criticize the agency for what was described as a lax attitude toward regulating the nanomaterials being used in new therapies and consumer products. Some of the FDA's harshest critics say that the FDA has become a cheerleader for nanotechnology instead of a watchdog for potentially hazardous products. Others noted that a variety of nanobio products have been incorporated into new therapies with little or nothing being done to track safety. And some cautioned that the FDA needs to do a better job of managing risk without throttling the field with over-regulation. The FDA has become something of a punching bag since the IOM released its report calling for wholesale reform of the agency. And each new criticism is adding pressure for significant change.

"New nano-enabled drugs and medical devices...place burdens on an oversight agency that is already stretched extremely thin," David Rejeski, director of the Project on Emerging Nanotechnologies, told the forum.

- Here's Newsweek's report on the FDA

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.